- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03984110
One Year Trial Evaluating Safety of Ozurdex With Eylea (COED)
April 8, 2024 updated by: Texas Retina Associates
The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative Trial
One Year Trial Evaluating Safety of Ozurdex With Eylea (COED)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this study, the investigators aim to compare the effects of combined use of intravitreal injections of Ozurdex every three3 months and monthly Eylea/aflibercept to monthly intravitreal injections of aflibercept alone as measured by improvement in central subfield thickness from baseline at Week 48 in eyes with center-involving Diabetic Macular Edema and best-corrected visual acuity of 20/40 or worse
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Karen Duignan
- Phone Number: 2146926941
- Email: kduignan@texasretina.com
Study Contact Backup
- Name: Sally M Arceneaux
- Phone Number: 2146926941
- Email: sarceneaux@texasretina.com
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75231
- Texas Retina Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Type 1 or 2 diabetic patients
- At least 18 years of age, understands the language of the informed consent, and is willing and able to provide written informed consent before any study procedures
- Pseudophakic or phakic lens status with intact posterior lens capsule and/or Nd: Yttrium Aluminum Garnet (YAG) laser capsulotomy that in the investigator's opinion is not likely to permit dislocation of Ozurdex implant into the anterior chamber
- Center-involving DME > 300 µm
- Baseline BCVA between 20/40 - 20/320
- Eyes with intraocular pressure (IOP) ≤ 21 and / or treatment with < 2 topical IOP-lowering medications (eyes with history of previous angle -closure or similar conditions that have been successfully treated with either laser or surgical intervention are allowed as long as the visual fields and optic nerves have been stable for > 1 year prior to study entry and the patient has been and can be safely dilated)
Exclusion Criteria:
- Patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
- Patients with known hypersensitivity to any components of Eylea or Ozurdex
- Patient has suffered from a stroke or transient ischemic attack (TIA) in the last 6 months
- Patients using topical anti-inflammatory medication for the duration of the study
- Patients with Anterior Chamber Intraocular Lens (ACIOL) and rupture of the posterior lens capsule
- Prior panretinal photocoagulation or macular laser treatments within 90 days of screening
- Previous vitrectomy
- Any ocular condition that in the opinion of the investigator would not permit improvement of visual acuity with resolution of DME (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates and/or poor foveal architecture suggestive of photoreceptor loss)
- Patients with retinal diseases other than diabetes that can affect macular edema
- Eyes with a history of advanced glaucoma (optic nerve head change consistent with glaucoma damage and/or glaucomatous visual field loss), uncontrolled ocular hypertension (baseline IOP > 21 mmHg despite use of ≥ 2 topical IOP-lowering medication)
- Eyes with a history of steroid response (i.e., increase of ≥ 5 mmHg IOP following topical steroid treatment)
- Female patients who are pregnant or breastfeeding
- Patients who are unable to attend scheduled follow-up visits throughout the 24-week study
- Any intravitreal anti-Vascular Endothelial Growth Factor (VEGF) treatment to study eye within 3 months prior to Day 1
- Use of systemic steroid, anti-VEGF or pro-VEGF treatment within 4 months prior to enrollment or anticipated use during the study (these drugs are prohibited from use during the study)
- History of any previous treatment in the study eye with an ocular corticosteroid implant (eg Iluvien, Ozurdex, Retisert)
- Has scarring from laser photocoagulation in the study eye that would compromise Visual Acuity (VA); or scarring or abnormality from other macular condition, in the investigator's medical judgement, would limit VA (such as an epiretinal membrane or macular hole)
- Has significant media opacity precluding evaluation of retina and vitreous in the study eye. This includes cataract that is felt to be a major contributor to reduced visual acuity and/or likely to undergo surgical repair within 3 months of randomization.
- Has any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study (eg, infection, uncontrolled elevated blood pressure, cardiovascular disease, poor glycemic control) or put the subject at risk due to study treatment or procedures
- Has had a myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 1 month before enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination of Ozurdex and Eylea
Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
|
Intravitreal injection
Other Names:
Intravitreal injection
Other Names:
|
Active Comparator: Eylea Monotherapy
Eyes receiving intravitreal injection of Eylea every month (as needed per protocol)
|
Intravitreal injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Central Subfield Thickness (CST)
Time Frame: 48 weeks
|
Change in Central Subfield Thickness (CST) on Spectral Domain-Optical Coherence Tomography (SD-OCT)
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monthly mean changes from baseline in CST
Time Frame: 48 weeks
|
Monthly mean changes from baseline in CST as measured by SD-OCT
|
48 weeks
|
CST
Time Frame: 12 weeks, 24 weeks, and 36 weeks
|
Change in CST
|
12 weeks, 24 weeks, and 36 weeks
|
Best Corrected Visual Acuity (BCVA)
Time Frame: 12 weeks, 24 weeks, 36 weeks, and 48 weeks
|
Change in Best Corrected Visual Acuity (BCVA)
|
12 weeks, 24 weeks, 36 weeks, and 48 weeks
|
Number of additional Intravitreal Therapy (IVT) aflibercept injections required over 48 weeks
Time Frame: 48 weeks
|
Number of additional Intravitreal Therapy (IVT) aflibercept injections required over 48 weeks
|
48 weeks
|
Monthly mean changes from baseline in BCVA
Time Frame: 48 weeks
|
Monthly mean changes from baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters read
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ashkan M Abbey, MD, Texas Retina Associates
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 11, 2019
Primary Completion (Actual)
October 27, 2022
Study Completion (Actual)
October 27, 2022
Study Registration Dates
First Submitted
June 11, 2019
First Submitted That Met QC Criteria
June 11, 2019
First Posted (Actual)
June 12, 2019
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Macular Edema
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Aflibercept
Other Study ID Numbers
- TRA-COED-19-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Ozurdex
-
Medical University of ViennaUnknownAcute Renal Failure | InfectionAustria
-
Texas Tech University Health Sciences CenterUniversity of Texas Southwestern Medical Center; National Center for Research...CompletedObesity | MycosesUnited States
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Retina Specialists, PCAllerganCompletedMacular Edema | Epiretinal Membrane | Retinal Edema | Cellophane MaculopathyUnited States
-
Northern California Retina Vitreous AssociatesAllerganCompletedUveitis | Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision DisordersIndia
-
University Health Network, TorontoCompleted
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Cataract | Vision Disorders | Macular Edema, Cystoid | Cystoid Macular Edema Following Cataract SurgeryIndia
-
Valley Retina InstituteUnknownCentral Retinal Vein Occlusion | Macular EdemaUnited States
-
Ottawa Hospital Research InstituteRecruiting